|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06AB10
|
|
gptkbp:CASNumber
|
163521-12-8
|
|
gptkbp:contraindication
|
gptkb:MAO_inhibitors
|
|
gptkbp:drugClass
|
antidepressant
selective serotonin reuptake inhibitor
serotonin receptor agonist
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
10 mg
20 mg
40 mg
|
|
gptkbp:genericName
|
vilazodone
|
|
gptkbp:halfLife
|
25 hours
|
|
gptkbp:hasMolecularFormula
|
C26H27N5O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Viibryd
|
|
gptkbp:interactsWith
|
CYP3A4 inhibitors
other serotonergic drugs
CYP3A4 inducers
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Allergan
gptkb:AbbVie
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young adults and children)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
dizziness
insomnia
dry mouth
sexual dysfunction
|
|
gptkbp:synonym
|
vilazodone hydrochloride
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
|
|
gptkbp:bfsParent
|
gptkb:Vilazodone
|
|
gptkbp:bfsLayer
|
7
|